POSTERS ASCO 2024

Cáncer de mama

Local, regional y adyuvante

Impact of CYP2D6 polymorphisms on adverse events in patients with breast cancer treated with tamoxifen: Insights from an early dose escalation trial in CYP2D6 poor metabolizers.

Impact of CYP2D6 polymorphisms on adverse events in patients with breast cancer treated with tamoxifen: Insights from an early dose escalation trial in CYP2D6 poor metabolizers.

Abstract: 547 Poster Bd #: 139

Poster

Descargar

Autor
Isabel Blancas, MD, PhD

Oncology Department, San Cecilio University Hospital

Compartir:

Una iniciativa científica de:

eco clover

Con el patrocinio de:

REGENERON